- NurExone Biologic (NRX) has received a notice of allowance from the United States Patent and Trademark Office for U.S. Patent Application NO. 17/042,44
- The patent covers and protects NurExone Exo-PTEN technology and its drug composition, as well as methods for non-invasive intranasal administration of exosome-based treatment
- The company plans to file additional patent applications with the USPTO as well as additional international patent applications (PCT)
- NurExone Biologic Inc. is a pharmaceutical company developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries
- NurExone Biologic Inc. was unchanged at $0.385 at 3:09 PM ET
NurExone Biologic (NRX) has received a notice of allowance from the United States Patent and Trademark Office (USPTO).
The notice of allowance is for U.S. Patent Application NO. 17/042,44.
The patent covers and protects NurExone Exo-PTEN technology and its drug composition, as well as methods for non-invasive intranasal administration of exosome-based treatment.
The patent discloses and claims groundbreaking inventions and methods in exosome technology. This includes the pharmaceutical compositions comprising extracellular vesicles, including exosomes, loaded with an exogenous inhibitor of phosphatase and tensin homolog (PTEN) inhibitor, as well as a method for treating neuronal injury or damage, including intranasal administration.
NurExone plans to file additional patent applications with the USPTO as well as additional international patent applications (PCT) in order to further strengthen NurExone’s intellectual property portfolio.
The patent was submitted by the Technion-Israel Institute of Technology and Ramot, a Tel Aviv University’s technology transfer company, and is part of NurExone’s licensed intellectual property portfolio.
“We are delighted that the USPTO has determined that the patent application covering our proprietary drugs and methods of administration satisfies the requirements for patentability,” said Dr. Lior Shaltiel, CEO of NurExone.
“The patent will enable us to strengthen the IP barrier protecting our core technology, including the source of the cells, loaded siRNA and method of administration,” he added.
Furthermore, at the company’s annual and special shareholders’ meeting held on December 19, 2022, among other decisions, the company’s shareholders approved the company’s equity incentive plan, which replaces the option plan of the company previously in effect.
NurExone Biologic Inc. is a pharmaceutical company developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries.
NurExone Biologic Inc. was unchanged at $0.385 at 3:09 PM ET.
